# A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

> **NCT06767683** · PHASE2,PHASE3 · RECRUITING · sponsor: **Alkermes, Inc.** · enrollment: 256 (estimated)

## Conditions studied

- Narcolepsy Type 1
- Narcolepsy Type 2
- Idiopathic Hypersomnia

## Interventions

- **DRUG:** ALKS 2680, 4mg
- **DRUG:** ALKS 2680, 6mg
- **DRUG:** ALKS 2680, 8mg
- **DRUG:** ALKS 2680, 10mg
- **DRUG:** ALKS 2680, 14mg
- **DRUG:** ALKS 2680, 18mg

## Key facts

- **NCT ID:** NCT06767683
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-27
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06767683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06767683, "A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06767683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*